Belimumab, marketed primarily under the brand name Benlysta, is a human monoclonal antibody that specifically targets and inhibits B-lymphocyte stimulator (BLyS), a cytokine essential for the survival of B cells. By reducing the number of B-cells, including autoreactive B-cells, it helps